Medpace Holdings SEC Filings

August J. Troendle, CEO, director and reported 10% owner of Medpace Holdings, Inc. (MEDP), reported open-market sales of common stock executed pursuant to a limit order during an open window period. On 08/29/2025 he sold 36,196 shares at a weighted average price reported as $475.9, leaving 925,799 shares directly beneficially owned. On 09/02/2025 he sold 1,197 shares at a weighted average price reported as $475.11, leaving 924,602 shares directly owned. He also may be deemed to indirectly own 4,733,019 shares held by Medpace Investors, LLC, of which he is sole manager with voting and investment control. The form was signed by an attorney-in-fact on 09/03/2025.

Form 144/A from Medpace Holdings, Inc. (MEDP) reports a proposed sale of 38,013 common shares through UBS Financial Services on 08/27/2025 with an aggregate market value of $18,056,175.00. The shares were acquired on 02/15/2022 by option exercise from the issuer and paid for in cash on 03/01/2022. The filing lists 28,741,609 shares outstanding for the class. The notice also discloses a recent sale by August J Troendle of 48,487 shares on 07/28/2025 for gross proceeds of $21,900,851.00. The filer attests there is no undisclosed material adverse information and includes the standard signature and legal warnings.

August J. Troendle, CEO, director and reported 10% owner of Medpace Holdings, Inc. (MEDP) reported a sale of 620 shares of the issuer's common stock on 08/27/2025 at $475 per share executed pursuant to a limit order placed during an open window period. After the sale the reporting person directly beneficially owns 961,995 shares and is reported as indirectly owning 4,733,019 shares through Medpace Investors, LLC, of which he is sole manager and controlling unit holder.

The filing clarifies that Troendle disclaims beneficial ownership of MPI-held shares except to the extent of his pecuniary interest and the Form 4 was signed by an attorney-in-fact on 08/28/2025.

Medpace Holdings insider transaction: Susan E. Burwig, Executive Vice President, Operations, reported exercising employee stock options and acquiring 10,000 shares of Medpace Holdings, Inc. (MEDP) on 08/26/2025 at a price of $107.93 per share. After the transaction she beneficially owns 67,500 shares directly. The filing also reports outstanding derivative holdings tied to employee stock options that reference 10,000 underlying shares and show 40,984 derivative securities beneficially owned following the reported activity. The form is signed by an attorney-in-fact on 08/28/2025.

Medpace Holdings, Inc. (MEDP) Form 144 summary: This notice reports a proposed sale of 38,013 common shares through UBS Financial Services on 08/27/2025. The filing lists an aggregate market value of $180,560,175 for the shares and shows 28,741,609 shares outstanding for the issuer. The shares were acquired by the seller on 02/15/2022 through an option exercise, with payment completed in cash on 03/01/2022. The filing also discloses a sale during the past three months: 48,487 shares sold on 07/28/2025 for $21,900,851. The form includes the standard signature representation that the seller is not aware of undisclosed material adverse information.

Medpace Holdings, Inc. (MEDP) director Cornelius P. McCarthy III reported a sale of 1,662 shares of Medpace common stock on 08/19/2025 under Form 4. The sale is coded S and executed at a weighted average price of $465.04 per share (individual trade prices ranged from $465.022 to $465.355). After the reported transactions, the reporting person beneficially owned 10,197 shares, held directly. The Form 4 was signed by an attorney-in-fact, Stephen P. Ewald, on 08/21/2025. The filer is identified as a director of the company and the filing indicates compliance with Section 16 reporting obligations.

Medpace Holdings, Inc. (MEDP) filed a Form 144 reporting a proposed sale of 1,662 common shares. The shares are held at Fidelity Brokerage Services and are scheduled for an approximate sale date of 08/19/2025 on the NASDAQ. The aggregate market value is reported as $772,893.91 and the total number of common shares outstanding is 28,093,026, meaning the shares represent approximately 0.0059% of outstanding stock. The shares were acquired on 02/08/2024 by a stock option exercise from the issuer, paid in cash on the acquisition date. The filer reports no securities sold in the past three months for the account.